Takeda Pharmaceutical Co. Ltd. recently announced that it will begin to consolidate the company’s Vaccine Business Unit (VBU) operations throughout the Boston and Cambridge area.
The consolidation will solidify both regional and global hubs while the organization advances and grows its vaccine programs, including dengue, noroviru, and seasonal influenza.
The VBUs based in the U.S. will be consolidated into the company’s Boston hub, a move that will improve collaboration and communication with all of the VBU’s divisions. It will also help the VBU to use the research and development presence based in Cambridge as well as the region’s biotech and pharmaceutical talent and ecosystem.
The regions chosen to serve as VBU’s global hubs include the Boston and Cambridge regions and Zurich. These will be the company’s main VBU sites outside of its native Japan. The company intends to maintain its other hubs in Singapore; Brazil; Hikari, Japan; Singen, Germany; and Durham, North Carolina.
“Takeda remains fully committed to the development of innovative vaccines that improve the lives of people around the world, including our norovirus, dengue and seasonal influenza candidate vaccines,” Takeda’s Vaccine Business Unit President Rajeev Venkayya said. “Our sites in Bozeman, Fort Collins, Madison and Deerfield have been instrumental in bringing our dengue and norovirus programs to late stages of clinical development. This consolidation will help us to achieve the efficiency and operational excellence needed to execute the Phase 3 clinical programs and set the stage for global commercialization of these vaccines.”